Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Year: 2018
Type: review
DOI: 10.1002/dmrr.3070
Institutions: Eli Lilly (Italy), University of Chieti-Pescara
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: GLP-1 receptor agonists, type 2 diabetes, exenatide, lixisenatide, albiglutide, dulaglutide, liraglutide, semaglutide, exendin-4, gastric emptying, glucose-dependent insulin secretion, glucagon secretion, weight loss, immunogenicity, gastrointestinal tolerance, medication adherence, drug administration routes
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W2889521172
